SkinHealth Systems Inc. SKIN
0.66
(0.02)
(2.94%)
as of 25 Sep
- Market cap
- $78.4M
- P/E
- 0.0×
Follow SKIN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.84 | 0.58 | 0.38 | 0.31 | |
P/FCF ratio |
7.40 | 5.43 | 4.89 | 5.37 | |
P/Operating CF |
26.18 | 11.56 | (20.48) | 33.48 | |
P/B ratio |
3.85 | 2.88 | 2.06 | 1.61 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.33 | 1.02 | 0.86 | 0.79 | |
EV/EBITDA |
217.85 | 37.57 | 14.25 | 9.49 | |
EV/Operating CF |
10.36 | 8.20 | 8.76 | 10.41 | |
EV/FCF |
11.77 | 9.51 | 10.90 | 13.74 | |
Quick Ratio |
3.95 | 1.37 | 1.45 | 1.34 | |
Current Ratio |
4.98 | 1.66 | 1.79 | 1.76 | |
Net Debt/EBITDA |
45.39 | 20.18 | 30.77 | 14.15 | |
Debt/Assets |
72.15% | 72.91% | 72.74% | 70.95% | |
Debt/Equity |
5.53 | 5.97 | 6.23 | 6.21 | |
Asset Turnover |
0.50 | 0.51 | 0.52 | 0.58 | |
Operating CF/Net income |
(0.87) | (1.88) | 0.84 | (1.00) | |
Capex/Depreciation |
(0.12) | (0.22) | (0.26) | (0.19) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2.40% | 2.04% | 1.70% | 1.95% | |
Selling, General and Administrative Expense of Revenue |
71.02% | 62.15% | 69.54% | 61.51% | |
Intangible Assets out of Total Assets |
0.33 | 0.32 | 0.34 | 0.32 | |
Share Based Compensation of Revenue |
3.47% | 4.35% | 3.20% | 4.01% | |
Graham Net Nets |
(0.51) | (0.74) | (1.23) | (1.52) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.52%) | (5.04%) | (4.49%) | (31.88%) | |
Free Cash Flow Yield |
13.51% | 18.40% | 20.46% | 18.61% | |
Revenue per Share |
0.56 | 0.65 | 0.51 | 0.56 | |
Operating CF per Share |
0.08 | 0.12 | (0.04) | 0.02 | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
0.07 | 0.11 | (0.06) | 0.01 | |
Cash per Share |
1.73 | 1.84 | 1.60 | 1.59 | |
Shareholders Equity per Share |
0.52 | 0.48 | 0.43 | 0.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.52 | 0.48 | 0.43 | 0.43 | |
Free Cash Flow |
8.56 | 13.81 | (7.20) | 1.47 | |
Working Capital |
246.46 | 123.24 | 122.49 | 127.04 | |
Capital Expenditures |
(1.08) | (1.38) | (1.65) | (1.20) | |
Net Current Asset Value |
(129.61) | (129.23) | (140.30) | (135.76) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.02 | 0.03 | 0.02 | |
Net Profit Margin |
(15.61%) | (9.84%) | (10.21%) | (3.70%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
31.04 | 25.95 | 21.89 | 23.38 | |
Average Payables |
20.19 | 18.79 | 19.51 | 19.51 | |
Average Inventory |
64.79 | 58.56 | 56.66 | 53.01 | |
Average Assets |
601.59 | 592.74 | 573.53 | 497.07 | |
Average Common Equity |
62.69 | 56.43 | 50.65 | 64.79 |
Columns are period end dates